Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141308 · ClinicalTrials.gov registry record
OCT in Rare Chorioretinal Diseases
A clinical trial of Central Serous Chorioretinopathy and Retinal Artery Occlusions, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT02141308: Recruiting study of Central Serous Chorioretinopathy and Retinal Artery Occlusions, sponsored by Oregon Health and Science University.
NCT02141308 is a study of Central Serous Chorioretinopathy and Retinal Artery Occlusions that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 150 participants, above the 59-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (154% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02141308, a study of Central Serous Chorioretinopathy and Retinal Artery Occlusions, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels. The purpose of measuring blood flow in the retina and choroid is to 1.) determine if rare diseases in these structures causes a change in blood flow compared to healthy eyes and 2.) find out if areas of changed blood flow line up with areas of damage that appear on conventional testing.
Primary Outcome
Determination whether disease affecting the retina and/or choroid shows a change in blood flow that differs from healthy eyes. Total retinal/choroidal blood flow will be measured in uL/min.
Conditions Studied
Study Locations (1)
Oregon
- Casey Eye Institute, Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2014-05 |
| Est. Completion | 2026-12 |
What NCT02141308 shows while recruiting
NCT02141308 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 59-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (154% higher).
The record links to 5 conditions, with Central Serous Chorioretinopathy appearing as the primary indexed condition, and to 0 interventions.
NCT02141308 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT02141308 about?
NCT02141308 is a clinical study titled "OCT in Rare Chorioretinal Diseases". This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels. The purpose of measuring blood flow in the retina and choroid is to 1.) determi...
What is the current status of trial NCT02141308?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2014-05. Estimated completion is 2026-12.
What conditions does trial NCT02141308 study?
This clinical trial studies the following conditions: Central Serous Chorioretinopathy, Retinal Artery Occlusions, Polypoidal Choroidal Vasculopathy, Retinal Arterial Macroaneurysm, Juxtafoveal Telangiecasia.
Who is sponsoring clinical trial NCT02141308?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02141308 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Serous Chorioretinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
Eplerenone for the Treatment of Central Serous Chorioretinopathy
COMPLETED · NA
-
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia